Short-Term Outcomes And Prognostic Factors Of Cataract-Combined Surgery With Istent Versus Istent Inject
Published 2022
- 40th Congress of the ESCRS
Reference: PO100
| Type: ESCRS 2022 - Posters
| DOI:
10.82333/rnne-s792
Authors:
Kuidong Kang* 1
, Jinhee Lee 2
, Jeongin Lee 1
, Jaeeun Lee 1
, Suk Won Oh 3
, Sungchun Kim 2
, Yong Chan Kim 4
1Jalbonun St. Mary's Eye Center,Incheon,Korea, Republic Of, 2Jlabonun St. Mary's Eye Center,Incheon,Korea, Republic Of, 3Jalbonun St. Mary's Eye Center,Incehon,Korea, Republic Of, 4Incheon St. Mary's Hospital,Incheon,Korea, Republic Of
Purpose
To analyze the therapeutic effects, prognostic factors, and complications that occurred after iStent® or iStent inject® implantation in South Korean glaucoma patients.
Setting
Incheon St. Mary's Hospital
Methods
We retrospectively analyzed 42 eyes of South Korean glaucoma patients, who were followed-up for more than 6 months after iStent® or iStent inject® implantation alone or combined with cataract surgery. Surgical success was defined as an intraocular pressure (IOP) ≤21 mmHg and an IOP reduction ≥20% from preoperative IOP levels.
Results
The cumulative success rate at 6 months after surgery was 45.3 ± 8.1% for iStent inject® alone (group A), 28.6 ± 13.1% for iStent® alone (group B), 81.2 ± 6.8% for iStent inject® combined with cataract surgery (group A-1), and 27.3 ± 21.8% for iStent® combined with cataract surgery (group B-1). Group A-1 showed a higher success rate than group B-1 (p = 0.007); the difference in success rates between groups A and B was not statistically significant (p = 0.579). When the success prognostic factors were analyzed by Cox regression analysis, the results showed that a higher preoperative IOP was associated with a higher surgical success rate (hazard ratio 0.80, p = 0.02).
Conclusions
In our patient group, iStent inject® was more effective than iStent® in combination with cataract surgery. The higher the preoperative IOP, the higher the surgical success rate; the results were significant.